- Home
- HRMY vs WRBY Comparison
HRMY vs WRBY Comparison
Compare HRMY & WRBY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HRMY | WRBY |
|---|---|---|
| Founded | 2017 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Ophthalmic Goods |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.1B |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | HRMY | WRBY |
|---|---|---|
| Price | $35.24 | $19.72 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 16 |
| Target Price | ★ $50.56 | $24.47 |
| AVG Volume (30 Days) | 934.4K | ★ 3.3M |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 50.44 | N/A |
| EPS | ★ 3.17 | 0.00 |
| Revenue | $825,944,000.00 | ★ $850,580,000.00 |
| Revenue This Year | $20.68 | $17.16 |
| Revenue Next Year | $15.93 | $14.75 |
| P/E Ratio | ★ $11.14 | $7,971.83 |
| Revenue Growth | ★ 21.13 | 14.55 |
| 52 Week Low | $25.52 | $13.63 |
| 52 Week High | $40.93 | $29.73 |
Technical Indicators
Market Signals| Indicator | HRMY | WRBY |
|---|---|---|
| Relative Strength Index (RSI) | 71.09 | 53.14 |
| Support Level | $32.77 | $16.95 |
| Resistance Level | $36.20 | $20.37 |
| Average True Range (ATR) | 1.11 | 0.84 |
| MACD | 0.17 | 0.54 |
| Stochastic Oscillator | 81.04 | 84.24 |
Price Performance
Historical ComparisonAbout HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About WRBY Warby Parker Inc.
Warby Parker Inc is a mission-driven, lifestyle brand that operates at the intersection of design, technology, healthcare, and social enterprise. The company predominantly derives revenue from the sales of eyewear products, optical services, and accessories. The firm sells products and services through its stores, website, and mobile apps. Revenue generated from eyewear products includes the sales of prescription and non-prescription optical glasses and sunglasses, contact lenses, eyewear accessories, and expedited shipping charges.